No Prescription |
 |
 | ||
|
Diamicron Generic Gliclazide |
|
| ||
No Prescription » Prescription Drugs 6 » Diamicron Generic Gliclazide Diamicron is used to control bloodglucose in patients with Type 2diabetes. Type 2 diabetes is alsoknown as non-insulin dependentdiabetes mellitus or maturity onsetdiabetes. In Type 2 diabetes bloodglucose stays too high because yourbody is not able to manage itproperly.Diamicron is used when diet andexercise are not enough to controlyour blood glucose.Diamicron can be used alone ortogether with insulin or othermedicines for treating diabetes. Buy Diamicron Generic Gliclazide and other Prescription Drugs 6 products online at Medstore. Buy Online at Medstore - Click Here!
About Diamicron Generic Gliclazide: Product Type: Prescription Drugs 6 Diamicron (Generic Gliclazide) Diamicron (Generic Gliclazide) Generic Gliclazide 80mg 200 Tablets 80mg 2 x 200 Tablets 80mg 100 Tablets 80mg 200 Tablets 80mg 400 Tablets Generic Gliclazide Diamicron
View more Prescription Drugs 6 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
